filename,source_row_index,headline,qui_tam_score,reason,key_facts,statute_violations,implicated_actors,federal_programs_involved,fraud_type
offlabel_1,2,Potential off‑label prescribing of Lipitor with high adverse event volume that may implicate Medicare billing fraud,60,"The record shows 64 adverse event reports for Lipitor, a drug with known off‑label indications. While the data do not explicitly mention Medicare billing or false claims, the high event volume and indication diversity raise a plausible pattern of off‑label prescribing that could be billed to Medicare. The lack of public disclosure and the need for further verification of billing practices place this case in the medium‑potential range.","64 adverse event reports for Lipitor in FDA FAERS; 4 distinct indications reported, suggesting off‑label use; Serious outcomes include 4 deaths, 1 life‑threatening event, and other severe events; No explicit Medicare billing data provided in the record",False Claims Act; Anti-Kickback Statute,Lipitor,,other
offlabel_2,3,"Potential off‑label marketing of JAKAFI with high adverse event volume and multiple indications, raising FDCA and False Claims Act concerns",85,"The record shows 50 adverse event reports linked to JAKAFI across five indications, indicating a systematic off‑label prescribing pattern. The high event volume and indication diversity suggest a deliberate marketing strategy that could have led to Medicare billing for non‑approved uses, creating strong FDCA and False Claims Act exposure. No public settlement or DOJ announcement is noted, keeping the first‑to‑file window open.","50 adverse event reports for JAKAFI in FDA FAERS; Reports span five distinct indications, none of which are FDA‑approved for JAKAFI; Serious outcomes reported in 5 of the 50 cases, indicating potential patient harm; Record explicitly calls for verification of Medicare coverage and prescribing patterns; No public disclosure or settlement noted",False Claims Act; FDCA,JAKAFI; Healthcare providers prescribing JAKAFI,Medicare; Medicaid,off-label marketing
offlabel_3,4,"Potential off‑label marketing of Humira with high adverse event volume and multiple indications, raising FDCA and False Claims Act concerns",85,"The record shows 31 adverse event reports linked to Humira across 10 indications, indicating a systematic off‑label marketing pattern. The high event volume and indication diversity suggest that the drug was promoted for non‑approved uses, potentially leading to Medicare/Medicaid claims for services paid under false pretenses. No public disclosure or settlement is noted, and the case is recent enough to be within the 6‑year statute of limitations.","31 adverse event reports for Humira in FDA FAERS; 10 distinct indications suggesting off‑label use; Serious outcomes reported in 5 cases (e.g., death, hospitalization); No public settlement or DOJ announcement; Case status listed as unfiled",False Claims Act; FDCA,Humira; Healthcare providers prescribing the drug,Medicare; Medicaid,off-label marketing
offlabel_4,5,"Potential off‑label prescribing scheme for LETAIRIS with 28 adverse events across 12 indications, likely involving Medicare beneficiaries",85,"The record shows a sizable cluster of adverse events (28) linked to 12 different indications, indicating systematic off‑label prescribing. The high event volume and indication diversity suggest a pattern that could involve Medicare beneficiaries, creating a strong False Claims Act opportunity. No public disclosure or settlement is noted, and the case is recent enough to be within the 6‑year statute of limitations.","28 adverse event reports filed with FDA FAERS for LETAIRIS; Reports span 12 distinct indications, indicating off‑label use; Serious outcomes reported in multiple cases (5, 1, 3, 6); No public settlement or DOJ announcement noted; Case status listed as unfiled",False Claims Act; Anti-Kickback Statute,LETAIRIS manufacturer,Medicare,off-label marketing
offlabel_5,6,"Potential off‑label marketing of Depakote ER with high adverse event volume and multiple indications, creating a strong False Claims Act opportunity if Medicare billing is involved",82,"The FAERS data shows a significant number of adverse events (24) linked to 11 different indications, indicating systematic off‑label use. If Medicare claims were submitted for these services, the case would violate both the False Claims Act and the FDCA. No public settlement or DOJ announcement is noted, and the record is recent enough to be within the 6‑year statute of limitations.",24 adverse event reports linked to Depakote ER; 11 distinct indications suggesting off‑label prescribing; No public disclosure or settlement noted; Record marked as unfiled and recent,False Claims Act; FDCA,Depakote ER,Medicare,off-label marketing
offlabel_6,7,"Potential off‑label prescribing scheme for OMNISCAN with 22 adverse events across 13 indications, possibly involving Medicare patients",78,"The record shows a high volume of adverse events and multiple indications for OMNISCAN, suggesting systematic off‑label use. While Medicare involvement is not explicitly stated, the next steps recommend verifying coverage and prescribing patterns, indicating a likely federal program connection. The pattern is not isolated, the damages could be significant, and no public disclosure or settlement has been noted.","22 adverse event reports linked to OMNISCAN; 13 distinct indications, indicating off‑label use; Serious outcomes reported in 5 cases; Case flagged for verification of Medicare coverage and prescribing patterns; No public settlement or DOJ announcement",False Claims Act; Anti‑Kickback Statute; Stark Law,"OMNISCAN manufacturer , prescribing physicians, healthcare facilities",Medicare; Medicaid,off-label marketing
offlabel_7,8,Potential off‑label prednisone prescribing scheme with 18 adverse events across 7 indications that may involve Medicare billing,75,"The FAERS data show a moderate volume of adverse events linked to off‑label use of prednisone across multiple indications, suggesting a systematic pattern.  If Medicare claims were submitted for these off‑label services, the case could trigger both FDCA and False Claims Act liability.  The lack of public disclosure and the need for further verification keep the score high but not at slam‑dunk level.",18 adverse event reports linked to prednisone in FAERS; 5 serious outcomes among the 18 events; 7 distinct indications suggesting off‑label use; No public settlement or DOJ announcement reported,False Claims Act; FDCA,Prednisone,Medicare,off-label marketing / prescribing
offlabel_10,11,Potential off‑label omeprazole prescribing with limited adverse event data – requires verification of Medicare involvement,50,"The record shows 15 adverse event reports for omeprazole, but there is no explicit evidence of Medicare/Medicaid billing or a documented pattern of false claims. The data are limited to FDA FAERS and lack dollar amounts, billing records, or a clear systematic practice. The score reflects the need for additional evidence to determine federal program involvement and potential damages.",15 adverse event reports for omeprazole in FDA FAERS; 5 serious outcomes reported among the 15 events; Indication diversity of 3 suggests possible off‑label use; No Medicare or Medicaid billing data provided,False Claims Act,Good Neighbor Pharmacy,,other
offlabel_11,12,Potential off‑label prescribing of prednisone that may involve Medicare billing and FDCA violations,70,"The record shows 15 adverse event reports linked to prednisone used for 8 different indications, indicating a pattern of off‑label use. If Medicare claims were submitted for these services, the case could violate both the FDCA and the False Claims Act. However, no direct evidence of Medicare billing is provided, so further investigation is required to confirm federal program involvement.",15 adverse event reports involving prednisone; 8 distinct indications suggesting off‑label use; 5 serious outcomes reported among the 15 events; Moderate adverse event volume indicates a potential pattern; Next steps recommend verifying Medicare coverage and prescribing patterns,False Claims Act; FDCA,Prednisone; FDA FAERS database,Medicare,off-label marketing
offlabel_14,15,Potential off‑label marketing of Rituxan with moderate adverse event volume and unclear Medicare involvement,50,"The record indicates 14 FAERS reports for Rituxan with serious outcomes, suggesting possible off‑label promotion. However, there is no explicit mention of Medicare/Medicaid billing or documented false claims, limiting the strength of a False Claims Act claim. The case remains unfiled and could be pursued if Medicare coverage or billing patterns are later confirmed.","14 FAERS adverse event reports for Rituxan; 5 serious outcomes, 6 serious outcomes reported; Indication diversity of 2 suggests off‑label use; No explicit Medicare/Medicaid billing data provided",False Claims Act; Anti-Kickback Statute,Rituxan,,off-label marketing
offlabel_15,16,Potential off‑label methotrexate marketing scheme with 13 serious adverse events across 8 indications that may have led to false Medicare claims,75,"The record shows a moderate volume of serious adverse events linked to methotrexate used off‑label for 8 different indications, suggesting a systematic marketing practice that could have driven Medicare billing. While no explicit Medicare claims data are provided, the next steps recommend verifying coverage and prescribing patterns, indicating a clear opportunity for further investigation under the False Claims Act.",13 adverse event reports linked to methotrexate; 5 serious outcomes among the 13 events; 8 distinct indications indicating off‑label use; Moderate adverse event volume suggests a pattern rather than isolated incidents; Next steps call for verification of Medicare coverage and prescribing patterns,False Claims Act; Anti‑Kickback Statute,Methotrexate manufacturer,Medicare,off-label marketing
offlabel_16,17,Potential off‑label prescribing of GILENYA with 13 adverse event reports and unclear Medicare involvement,50,"The record indicates 13 adverse event reports for GILENYA, a drug with known off‑label use concerns.  No explicit Medicare/Medicaid billing data or documented false claims are present, and the adverse events alone do not establish a clear pattern of fraudulent billing.  The case is therefore considered medium potential pending further investigation into prescribing patterns and federal program involvement.",13 adverse event reports for GILENYA in FDA FAERS; 5 serious outcomes reported among the 13 events; Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided in the record,False Claims Act; Anti-Kickback Statute,GILENYA,,other
offlabel_17,18,Potential off‑label etoposide prescribing that may generate false Medicare claims,55,"The record indicates 13 adverse event reports for etoposide, a drug with only one indication listed. While no direct Medicare billing data is provided, the next step explicitly calls for verification of Medicare coverage and prescribing patterns. If off‑label use is widespread among Medicare beneficiaries, it could create a False Claims Act exposure. The lack of documented billing amounts or patterns keeps the score in the medium range.","13 adverse event reports for etoposide in FAERS; 5 serious outcomes among those reports; Only one indication listed for the drug, suggesting off‑label use; Next steps call for verifying Medicare coverage and prescribing patterns",False Claims Act,Unknown provider using etoposide off‑label,,off-label marketing / potential false claims
offlabel_19,20,Potential off‑label prescribing of lisinopril with 11 adverse event reports – requires verification of Medicare involvement,50,"The record indicates 11 adverse event reports for lisinopril with serious outcomes, suggesting possible off‑label use. However, there is no explicit mention of Medicare/Medicaid billing or documented claims fraud, and the data come from FDA FAERS rather than provider billing records. The case is therefore a medium‑potential opportunity that needs further evidence of federal program involvement and billing patterns.","11 adverse event reports for lisinopril in FDA FAERS; Serious outcomes reported (2, 1, 3, 6); Indication diversity of 3 suggests possible off‑label prescribing; No direct evidence of Medicare/Medicaid billing or claims fraud",False Claims Act; Anti-Kickback Statute,Unknown provider prescribing lisinopril,,other
offlabel_23,24,Potential off‑label marketing of Pradaxa with limited adverse event data and unclear Medicare billing patterns,55,"The record indicates off‑label prescribing of Pradaxa with a modest number of adverse events, but lacks direct evidence of Medicare/Medicaid billing fraud or documented financial loss. The case may involve FDCA violations and could trigger False Claims Act liability if Medicare claims were submitted for off‑label use, but the current evidence is weak and requires further investigation.",10 adverse event reports for Pradaxa in FAERS; Serious outcomes reported in 3 of the 10 cases; Indication diversity of 4 suggests possible off‑label use; No direct Medicare or Medicaid billing data provided,FDCA,Pradaxa manufacturer: Allergan/AbbVie,,off-label marketing
offlabel_24,25,Potential off‑label prescribing of cyclophosphamide that may trigger false claims for Medicare billing,55,"The record shows a pattern of cyclophosphamide prescribed for six different indications, with nine adverse events and multiple serious outcomes. While the data come from FDA FAERS and do not yet confirm Medicare billing, the diversity of indications suggests possible off‑label use that could be billed to federal programs. The case is unfiled and no public settlement or DOJ announcement has been noted, but further evidence of Medicare claims is required to confirm a viable False Claims Act claim.","Cyclophosphamide prescribed for six distinct indications; Nine adverse events reported, five serious outcomes; Off‑label use may be billed to Medicare/Medicaid if not medically justified; Record originates from FDA FAERS, indicating potential regulatory concern",False Claims Act; FDCA,Unnamed prescribing provider,Medicare; Medicaid,off-label marketing
offlabel_44,26,Potential off‑label prescribing of EXJADE across multiple indications with serious adverse events,55,"The record shows six adverse events, five of which were serious, linked to EXJADE prescribed for five different indications. While no explicit Medicare/Medicaid billing data is provided, the diversity of indications and serious outcomes suggest a pattern that could involve federal program claims if off‑label use was billed. The lack of public disclosure and the need for further verification keep this case in the medium‑potential range.","EXJADE was reported in six FAERS cases with five serious outcomes; The drug was used for five distinct indications, indicating off‑label prescribing; No public settlement or DOJ announcement has been made; The case is currently listed as unfiled",False Claims Act; FDCA,EXJADE manufacturer,,off-label marketing
